openPR Logo
Press release

OHMX.bio and Fujirebio Europe Receive Grant of 720K EURO to Incorporate Third Generation Sequencing into Clinical In Vitro Diagnostics Platform

12-08-2020 04:36 PM CET | Health & Medicine

Press release from: Halsin Partners

/ PR Agency: Halsin Partners
Ghent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they have been awarded a 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. The project, called IVD-seq, will initially focus on a cost-efficient, accurate and portable IVD modular solution for highly polymorphic regions. The partners aim to expand the resulting platform solution to other molecular diagnostic markers.

The IVD-seq project brings together a unique and complementary partnership of clinical IVD expertise from Fujirebio Europe and third generation sequencing based-omics solutions from OHMX.bio to develop a best-in-class IVD solution that completely operates from Flanders, Belgium.

“Next generation sequencing (NGS) has already been incorporated into clinical in vitro diagnostics so there is a significant opportunity to explore the benefits and potential advantages of building an IVD platform incorporating the third generation sequencing (TGS) platforms,” said Prof. Gerben Menschaert, Chief Scientific Officer and co-founder of OHMX.bio. “Working on this project will illustrate the broad capabilities that OHMX.bio can provide to its partners and we very much look forward to combining our expertise with that of Fujirebio Europe, a true leader in diagnostics.”

“TGS is already providing more accurate and actionable genetic sequencing information. By incorporating this cutting-edge approach into clinical diagnostics, we believe this research could take advantage of this improvement in data, resulting in better diagnostic information that can be utilized for the benefit of patients,” stated Christiaan De Wilde, Chief Executive Officer of Fujirebio Europe.

The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. In addition, the project will strive toward multiplexing related clinical markers within one IVD solution and indexing this in a cost-efficient way over multiple different patient samples.
About Fujirebio
Fujirebio is a global leader in the field of high-quality IVD testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.

Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is a wholly-owned subsidiary of H.U. Group Holdings Inc. (formerly known as Miraca Holdings Inc. and listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.

Martelaarslaan 408
9000 Gent
Belgium

Gerben Menschaert
OHMX.bio
+32 478 46 45 43
Gerben.Menschaert@ohmx.bio

About OHMX.bio
OHMX.bio offers customers state-of-the-art solutions to their biological questions using cutting-edge “omics” technologies - transcriptomics, translatomics, proteomics and (epi)genetics. We provide start-to finish project management from sample preparation to customized data analysis and data reporting.

Founded in Ghent in 2019, as a spin-off initiative of the Ghent University, OHMX.bio provides genome-wide maps using the latest sequencing (Illumina and Oxford Nanopore) and mass spectrometry technologies. In particular, we are world-leaders in unravelling genome-wide maps of translated mRNA, a technique called ribosome profiling or RIBO-seq. We constantly develop our portfolio offering novel technologies, such as direct DNA and RNA sequencing from Oxford Nanopore Technologies, focussing on the application areas of clinical diagnostics, epigenetics and microbiomics analysis. We maintain a strong collaborative network of academic experts. Further information can be found at https://ohmx.bio/.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OHMX.bio and Fujirebio Europe Receive Grant of 720K EURO to Incorporate Third Generation Sequencing into Clinical In Vitro Diagnostics Platform here

News-ID: 2204503 • Views:

More Releases from Halsin Partners

Transimmune Secures $5m Funding to Enhance mRNA Vaccination with Novel Dendritic Cell Therapy
Transimmune Secures $5m Funding to Enhance mRNA Vaccination with Novel Dendritic …
• Expansion of existing Bill & Melinda Gates Foundation relationship aims to design mRNA guided therapies that more directly mirror the natural immune system response to antigenic threats. • Combination of "physiologic" dendritic cells with mRNA programming could potentiate mRNA vaccination potency in therapeutic settings. Düsseldorf, Germany, September 20th, 2023 - Transimmune AG, a pioneering dendritic cell therapy company, announced today a $5 million investment from the Bill & Melinda Gates Strategic Investment Fund.
NETRIS Pharma led consortium awarded €1.2 million Eurostar grant to explore ne …
ACTaNet project will focus on chronic bone pain in arthritis and cancer initially leveraging anti-netrin-1 antibody NP137 January 19, 2023 Lyon, Copenhagen and Stockholm - NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of drugs based on dependence receptor biology, today announced that a consortium of leading European academic institutions and biotech companies have been awarded a €1.2 million Eurostar grant for ACTaNet. The ACTaNet project aims to
Allelica’s Polygenic Risk Score Published in Circulation Identifies People at …
Rome, Italy, March 8, 2021 – Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRS) for personalised medicine, today announced publication of a study in Circulation (Vol. 143, Issue 10) showing that the effect of LDL cholesterol on a person’s risk of having a heart attack depends on their genes. Using Allelica’s proprietary PRS analysis software, the data showed that combining information on an individual’s genetic
Neem Biotech Presents Data Showing Effectiveness of the Quorum Sensing Inhibitor …
Ajoene found to reduce virulence factor secretion, destabilise mature bacterial biofilms, allowing re-sensitisation to antibacterial agents Neem Evaluating Drug Candidates based on Ajoene for Clinical Evaluation Against Wound Infections Cardiff, UK|24 June 2019 Neem Biotech, a company focused on developing novel solutions to address antimicrobial resistance, announced today the presentation of data demonstrating the effectiveness of Ajoene against the spread of infection in chronic wounds at ASM Microbe 2019 in San Franciso (20-24

All 5 Releases


More Releases for IVD

In Vitro Diagnostics (IVD) Market
With the watchful use of established and advanced tools such as SWOT analysis and Porter's Five Forces Analysis, this market report has been structured. While preparing this In Vitro Diagnostics (IVD) Market research report, few of the attributes that have been adopted include highest level of spirit, practical solutions, committed research and analysis, innovation, integrated approaches, and most up-to-date technology. Every possible effort has been taken while researching and analysing
Companion Animal IVD Market - Guiding the Path to Optimal Health: Empowering Vet …
Newark, New Castle, USA - new report, titled Companion Animal IVD Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Companion Animal IVD market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Companion Animal IVD market. The report offers an overview of
IVD Market 2021 | Detailed Report
The IVD market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The IVD report also incorporates the current and future global market outlook in the emerging and developed markets. Moreover, the report also investigates regions/countries expected to witness the fastest growth rates during the forecast period. The IVD research report also provides insights of different regions that are contributing market growth.
Liquid Biopsy IVD Market 2021 | Detailed Report
According to Market Study Report, Liquid Biopsy IVD Market provides a comprehensive analysis of the Liquid Biopsy IVD Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures) of Liquid Biopsy IVD Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4623688 The report provides a
Infectious Disease IVD Market – Forecast to 2026
The findings reviewed by GME stated that the Global Infectious Disease In-Vitro Diagnostics Market would grow at a CAGR value of 4.6 percent from 2021 to 2026. The increasing geriatric population is the primary driving factor for the infectious disease in-vitro diagnostics market. Besides, the increasing number of infectious diseases, launch of advanced testing kits and beneficial features attributed by IVDs are propelling growth in the market. Browse 159 Market
Asia IVD Market
According to a new report published by Allied Market Research, the Asia Pacific In-vitro diagnostics market was valued at $12.9 billion in 2015, and is expected to reach $19.0 billion registering a CAGR of 5.6% during 2016 to 2022. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario. Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1256 The Asia-Pacific IVD market is